Tima Davidson
YOU?
Author Swipe
View article: Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series
Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series Open
Background Borderline resectable stage III non-small cell lung cancer (NSCLC) poses significant clinical challenges. This study evaluated the outcomes of patients receiving neoadjuvant chemoradiation (NA-CRT), durvalumab, and surgery. Mate…
View article: The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous Nephropathy
The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous Nephropathy Open
Anti-PLA2R antibodies (Ab) are a diagnostic and prognostic biomarker in primary membranous nephropathy (PMN). We assessed the relationship between the levels of anti-PLA2R Ab at diagnosis and different variables related to disease activity…
View article: The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer
The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer Open
Background: Numerous papers have described 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)’s sensitivity in identifying prostate cancer (PCa) recurrence. This study aimed to characte…
View article: Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting
Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting Open
Immune checkpoint inhibitors (ICIs) are now the standard of care for metastatic urothelial carcinoma (mUC) patients. Our aim was to describe the activity of ICIs in mUC and find the clinical parameters associated with response. This is a r…
View article: Reply to Veerman et al. Comment on “Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410”
Reply to Veerman et al. Comment on “Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410” Open
We thank the commenters for their important insights [...]
View article: Vedolizumab-related arthralgias in patients with inflammatory bowel disease: A systematic review
Vedolizumab-related arthralgias in patients with inflammatory bowel disease: A systematic review Open
Aim: Multiple papers have reported the development of new-onset arthralgias with vedolizumab (VDZ) for the treatment of inflammatory bowel disease (IBD). Other studies have shown that VDZ may help in preexisting enteropathic spondyloarthro…
View article: Immunoglobulin G4 related disease and pancreatic malignancy - an association or two independent processes?
Immunoglobulin G4 related disease and pancreatic malignancy - an association or two independent processes? Open
Immunoglobulin G4 related disease (IgG4-RD) is a rare multisystem inflammatory disease, in which one of the main gastrointestinal manifestations is autoimmune pancreatitis (AIP) type 1. AIP type 1 is correlated with a clinical presentation…
View article: Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates
Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates Open
Purpose: to evaluate a unique subpopulation of radical prostatectomy (RP) candidates with “negative” prostate 68Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT) imaging scans …
View article: Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching
Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching Open
Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combi…
View article: The Utility of 18FDG-PET/CT in Diagnosing Fever of Unknown Origin: The Experience of a Large Tertiary Medical Center
The Utility of 18FDG-PET/CT in Diagnosing Fever of Unknown Origin: The Experience of a Large Tertiary Medical Center Open
Fever of unknown origin (FUO) poses a diagnostic challenge, and 18-fluorodexoyglucose positron emission tomography with computed tomography (18FDG-PET/CT) may identify the source. We aimed to evaluate the diagnostic yield of 18FDG-PET/CT i…
View article: 18F-FDG PET-CT postoperative changes after maxillectomy: Findings and pitfalls in interpretation
18F-FDG PET-CT postoperative changes after maxillectomy: Findings and pitfalls in interpretation Open
Objective: We investigated the findings and pitfalls of FDG-PET/CT scanning after maxillectomy with reconstruction/rehabilitation procedures, in patients with head and neck malignancies treated during nine years at one tertiary medical cen…
View article: PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases Open
SBRT is a highly effective and safe method for treatment of prostate cancer bone metastases. More studies are required to determine if SBRT provides greater clinical benefit than standard fractionation for oligometastatic prostate cancer p…
View article: Post‐mastectomy surveillance of <i>BRCA1</i> / <i>BRCA</i> 2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients
Post‐mastectomy surveillance of <i>BRCA1</i> / <i>BRCA</i> 2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients Open
Female BRCA1/BRCA2 mutation carriers may elect bilateral risk-reducing mastectomy. There is a paucity of data on yield of imaging surveillance after risk-reducing mastectomy. This retrospective study focused on female BRCA1/BRCA2 mutation …
View article: The Usefulness of PET/CT In Detecting and Managing Cancers With Unknown Primary Site Depends on Histological Subtype
The Usefulness of PET/CT In Detecting and Managing Cancers With Unknown Primary Site Depends on Histological Subtype Open
Introduction: We assessed the role of PET/CT in identifying and managing cancer of unknown primary site (CUP). Methods: We reviewed 64 patients' PET/CT scans with CUP performed during 2012–2019. Results: The median age was 65 years. Of 138…
View article: The utility of PET/CT in diagnosing fever of unknown origin: The experience of a large tertiary medical center
The utility of PET/CT in diagnosing fever of unknown origin: The experience of a large tertiary medical center Open
Background: Fever of unknown origin (FUO) is a diagnostic challenge. Positron emission tomography with computed tomography (PET/CT) is expensive and not widely available. We aimed to evaluate the diagnostic yield of PET/CT in the workup of…
View article: A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer Open
Background Prostate cancer is a common malignancy of the elderly, and with the aging of the population, the need is growing for therapies suitable for this age group. Lutetium-177–prostate-specific membrane antigen (Lu-PSMA), a radiolabele…
View article: Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer Open
Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling targeted radiation therapy to metastatic prostate lesions. Our objective was to retrospect…
View article: Reexpansion of atelectasis caused by use of continuous positive airway pressure (CPAP) before radiation therapy (RT)
Reexpansion of atelectasis caused by use of continuous positive airway pressure (CPAP) before radiation therapy (RT) Open
This is the first reported use of CPAP for reexpansion of atelectasis before RT planning and treatment. Reexpansion of atelectasis improved RT planning, decreased dose to uninvolved lung, and removed the need for replanning. Further study …